Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01171027
Other study ID # NOTES® Trial
Secondary ID
Status Recruiting
Phase N/A
First received July 26, 2010
Last updated November 30, 2011
Start date July 2010
Est. completion date September 2012

Study information

Verified date November 2011
Source Natural Orifice Surgery Consortium for Assessment and Research
Contact Michael Kochman, MD
Phone 215 662 4279
Email michael.kochman@uphs.upenn.edu
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study is designed to be a United States multicenter prospective randomized controlled non-inferiority evaluation of transgastric and transvaginal Natural Orifice Translumenal Endoscopic Surgery (NOTES) cholecystectomy compared to laparoscopic cholecystectomy in elective surgery patients. Up to 200 patients will be enrolled to obtain 70 NOTES cholecystectomies (35 transgastric and 35 transvaginal) and 70 laparoscopic cholecystectomies on a randomized basis. In order to evaluate the hypothesis that NOTES cholecystectomy has equivalent safety and efficacy to laparoscopic cholecystectomy, clinical and administrative outcomes will be measured.


Description:

Primary To assess the safety and efficacy of transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.

To assess pain associated with transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.

Secondary To assess cosmesis associated with transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.

To assess objective operative cost and logistical comparisons between transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.

To identify unforeseen barriers to transgastric or transvaginal surgery adoption.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date September 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Competent male or female subjects, between the ages of 18-75 and who present for elective cholecystectomy will be offered participation in this study.

- Male subjects must be willing to have the cholecystectomy by either the laparoscopic or transgastric NOTES approach.

- Female subjects must be willing to have the cholecystectomy by either the laparoscopic or either the NOTES approaches (transgastric and/or transvaginal) being performed at the site.

- Patients offered participation in this study must provide written, informed consent and meet the following criteria prior to randomization.

- Diagnosis of benign gallstone disease which requires cholecystectomy.

- ASA Class 1 or 2.

- Willingness to have laparoscopic cholecystectomy performed and have research data collected for control group.

- Willingness to have abdomen photographed (for cosmesis assessment).

- For sites performing transgastric NOTES approach

- Willingness to have cholecystectomy performed via NOTES transgastric approach.

- Willingness to have NOTES procedure videotaped.

- For sites performing transvaginal NOTES approach - Female subjects only

- Willingness to have cholecystectomy performed via NOTES transvaginal approach.

- Willingness to have intra-abdominal procedure digitally recorded.

- Pelvic examination in the past 12 months without significant pathology.

Exclusion Criteria:

- Pregnant women.

- Obese patients (BMI > 35).

- Patients with severe medical comorbidities (ie, NOT ASA Class 1 or 2) will be excluded such as:

- Chronic renal failure

- Chronic liver disease

- Congestive heart failure

- Patients with a presumed gallbladder malignancy.

- Patients with a history of prior open abdominal or laparoscopic or transvaginal surgery. However patients with prior appendectomy, tubal ligation or Cesarean section will be included.

- Patients who are taking immunosuppressive medications and/or immunocompromised.

- Patients with a prior history of perineal trauma leading to significant alteration of vaginal anatomy.

- Patients with a history of ectopic pregnancy, pelvic inflammatory disease, large fibroids or severe endometriosis.

- Patients with known common bile duct stones. (ie, not cleared prior to surgery). Patients with common bile duct stones discovered intra-operatively will remain in the study.

- Patients on anticoagulation drugs other than once daily aspirin. Abnormal blood coagulation tests. Minimal abnormalities may be allowed at the discretion of site principal investigator.

- Gallstones> 2.5cm in diameter.

- Presence of untreated esophageal stricture.

- Surgically altered gastric anatomy or severe uncorrected paraesophageal types 2, 3 or 4.

- Unwillingness to consent to NOTES procedure(s).

- Acute cholecystitis or cholangitis

- For sites performing transgastric NOTES approach

- Contraindicated for esophagogastroduodenoscopy (EGD).

- Patients with hypersecretory states.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Intervention

Procedure:
NOTES Cholecystectomy
The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
Laparoscopic Cholecystectomy
This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.

Locations

Country Name City State
United States Northwestern University Chicago Illinois
United States Ohio State University Columbus Ohio
United States Yale University New Haven Connecticut
United States Oregon Clinic Portland Oregon
United States University of California at San Diego San Diego California
United States Baystate Medical Center Springfield Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Natural Orifice Surgery Consortium for Assessment and Research American Society for Gastrointestinal Endoscopy

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the safety and efficacy of transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy. 4 weeks post surgery Yes
Secondary To assess pain associated with transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy. 4 weeks post surgery No

External Links